Abstracts Archive - Page 902 of 2425 - ACR Meeting Abstracts

Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 2156 • 2019 ACR/ARP Annual Meeting
Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome
Qingping Yao¹ and Apostolos Kontzias ¹, ¹Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321), formerly termed nucleotide-binding, oligomerization domain 2(NOD2)-associated autoinflammatory disease, has become increasingly recognized. The disease has been reported in America,…
Abstract Number: 2157 • 2019 ACR/ARP Annual Meeting
Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival
Karmela Kim Chan ¹, Aidan Tirpack ¹, Caroline Benson ¹, Gregory Vitone ¹, Jackie Finik ², Vivian Bykerk ³, Susan Goodman ⁴, Laura Donlin ⁵, Deepak Rao ⁶ and Anne Bass⁴, ¹Hospital For Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Hospital for Special Surgery, New York City, NY, ⁴Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital For Special Surgery, New York, NY, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that steroid dose1and rheumatoid factor positivity2 impact cancer survival in checkpoint inhibitor (CI)-treated patients (with CI-associated hypophysitis, and in all-comers with non-small…
Abstract Number: 2158 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Janet Roberts¹, Daniel Ennis ², Marie Hudson ³, Carrie Ye ⁴, Alexandra Saltman ⁵, Sabrina Hoa ⁶, Janet Pope ⁷, Megan Himmel ², Nancy Maltez ⁸, Aurore Fifi-Mah ⁹, Annaliese Tisseverasinghe ¹⁰, Robert Rottapel ¹¹, Karam Al Jumaily ¹², Christina Ly ¹³, Liliana Cartagena ¹⁴ and Shahin Jamal ¹⁵, ¹Dalhousie University, Halifax, NS, Canada, ²University of Toronto, Toronto, ON, Canada, ³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Western University, London, ON, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Alberta, edmonton, Canada, ¹³McGill University, Montreal, Canada, ¹⁴Arthritis Research Canada, Vancouver, Canada, ¹⁵University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by harnessing the immune system to fight cancer. They are associated with the development of autoimmune…
Abstract Number: 2159 • 2019 ACR/ARP Annual Meeting
Pachymeningitis in Rheumatic Disease
Rachel Kneeland¹, John Berry ², Sydney Brandwein ² and Monika Starosta ², ¹Department of Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, ²Advocate Lutheran General Hospital, Park Ridge, IL
Background/Purpose: Pachymeningitis is a rare complication of rheumatic disease. Patients present with hearing loss or other neurologic complications. Diagnosis is made by thickening of dura…
Abstract Number: 2160 • 2019 ACR/ARP Annual Meeting
Myopenia Is an Independent Risk Factor for Rotator Cuff Tear and Shoulder Dysfunction in Elderly People : Data from NAMGARAM Cohort
Yun-Hong Cheon¹, Young Sun Suh ², Mingyo Kim ¹, Ki-Soo Park ³ and Sang-Il Lee ¹, ¹Divison of Rheumatology, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea, ²Divison of Rheumatology, Gyeongsang National University Hospital, Changwon, Changwon, Republic of Korea, ³Preventive Medicine, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea
Background/Purpose: Myopenia refers to decline in muscle mass with age, causing significant impairment in the ability to carry out normal daily functions. Rotator cuff tear…
Abstract Number: 2161 • 2019 ACR/ARP Annual Meeting
Perioperative Glucocorticoid Management in Patients with Rheumatologic Diseases Undergoing Elective Joint Surgeries
Rashmi Dhital¹, Priyadarshani Sharma ², Izza Mir ² and Anthony Donato ², ¹Reading Hospital ,PA, Shillington, PA, ²Reading Hospital, PA, Reading
Background/Purpose: Over 7 million Americans are estimated to suffer from inflammatory rheumatologic diseases and the rate of joint arthroplasties are nearly 50 % higher among…
Abstract Number: 2162 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)
Shuji Asai¹, Toshihisa Kojima ¹, Nobunori Takahashi ¹ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…
Abstract Number: 2163 • 2019 ACR/ARP Annual Meeting
Prevalence of Postoperative Anemia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Undergoing Total Knee Arthroplasty: A Study of National Inpatient Sample 2010-2014
Karan Jatwani ¹, Karan Chugh ², Bikramjit Bindra ³ and Shraddha Jatwani², ¹Mount Sinai West - St Luke’s Hospital, New York, ²St. Vincent Evansville, Evansville, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Total knee arthroplasty (TKA) is a valuable option for improving function and pain control in patients with end-stage arthritis, especially those with inflammatory arthritis…
Abstract Number: 2164 • 2019 ACR/ARP Annual Meeting
Lumbar Spinal Stenosis in Patients with Wild-type Transthyretin Cardiac Amyloidosis
Ana B Arevalo¹, Faris Haddadin ¹, Shane Murray ¹, Gustavo Contreras ¹, Yiming Luo ¹ and Yousaf Ali ¹, ¹Mount Sinai St. Luke's - West/ Icahn School of Medicine, New York, NY
Background/Purpose: Senile systemic amyloidosis (SSA) derived from wild-type transthyretin (TTR) is a debilitating autosomal dominant disease leading to motor disability within 5 years and fatal…
Abstract Number: 2165 • 2019 ACR/ARP Annual Meeting
Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults
Ailing Yang¹, Wei Yuet ², LaDonna Saxon ³, James LePage ³, Liana Fraenkel ⁴, Manney Reid ⁵ and Una Makris ⁶, ¹UT Southwestern Medical Center, Dallas, ²UNT Health Science Center, Fort Worth, ³Dallas VA Medical Center and UT Southwestern Medical Center, Dallas, ⁴Yale School of Medicine and VA Connecticut Healthcare System, New Haven, ⁵Weill Cornell Medicine, New York City, ⁶UT Southwestern Medical Center and Dallas VA Medical Center, Dallas
Background/Purpose: Chronic low back pain (cLBP) is the 2nd most common reason for physician visits; annual related costs exceed $100 billion and are expected to…
Abstract Number: 2166 • 2019 ACR/ARP Annual Meeting
Multimodal Edema Management After Total Knee Arthroplasty: A Pilot Study
Joel Carmichael¹, Michael Bade ¹ and Jennifer Stevens-Lapsley ¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: The ideal treatment of swelling after TKA is unclear. The purpose of this pilot study was to determine the feasibility and initial efficacy of…
Abstract Number: 2167 • 2019 ACR/ARP Annual Meeting
A Randomised Controlled Clinical Trial Comparing the Effectiveness of 6 and 12 Weeks of a Shoulder Specific Exercise Programme for Patients with Rotator Cuff Related Shoulder Pain
Sandra Keyes¹, Noreen Walsh ¹ and Mark Phelan ¹, ¹South Infirmary Victoria University Hospital, Cork, Ireland
Background/Purpose: Research has shown loaded exercise programmes to be beneficial for patients with rotator cuff related shoulder pain in terms of improving shoulder function, self-reported…
Abstract Number: 2168 • 2019 ACR/ARP Annual Meeting
Early Start of Outpatient Physical Therapy After Knee Replacement Is Associated with More Objectively-measured Steps and Time Spent Upright
Christine Pellegrini¹, Nicholas Mook ², Katherine DeVivo ² and Deborah Brown ³, ¹University of South Carolina, Columbia, SC, ²University of South Carolina, Columbia, ³Prisma Health, Columbia, SC
Background/Purpose: After knee replacement, patients often receive physical therapy in-home or at a rehabilitation facility shortly after surgery and then transition to outpatient physical therapy.…
Abstract Number: 2169 • 2019 ACR/ARP Annual Meeting
Reporting of Adverse Events in Randomized Controlled Trials of Therapeutic Exercise for Knee Osteoarthritis: A Systematic Review
Johan vonHeideken ¹ and Maura D. Iversen², ¹Karolinska Institutet, Stockholm, Sweden, ²Northeastern University, Boston
Background/Purpose: CONSORT guidelines recommend the reporting of adverse events (AEs) and drop outs, along with a description of each. However, the application of these guidelines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].